Skip to main content

Table 1 General characteristics of the population included in the study

From: Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes

 

NHIS

NHIS + Eze

HIS

HIS + Eze

p value*

N = 27,795 (74%)

N = 2815 (7%)

N = 6578 (17%)

N = 645 (2%)

Age in years mean (S.D.)

72.6 (11)

69.4 (11)

71.7 (11)

66.9 (11)

 < 0.001

Female n (%)

14,145 (51)

1202 (43)

2157 (33)

196 (30)

 < 0.001

Age < 80 years n (%)

20,695 (75)

2411 (86)

5026 (76)

597 (93)

 < 0.001

Hypertension n (%)

21,712 (78)

2296 (82)

5789 (88)

579 (90)

 < 0.001

Diabetes n (%)

7718 (28)

772 (27)

1821 (28)

148 (23)

N.S

GFR (ml/min/1.73 m2) mean (S.D.)

89.9 (31)

85.1 (30)

89.4 (32)

91.9 (31)

 < 0.001

HbA1c (mmol/mol) mean (S.D.)

47.6 (13)

46.6 (12)

46.2 (13)

45.0 (12)

 < 0.001

CVD n (%)

2592 (9)

573 (20)

1816 (28)

287 (45)

 < 0.001

Cerebrovascular disease n (%)

2355 (9)

257 (9)

1838 (28)

72 (11)

 < 0.001

Peripheral vascular disease n (%)

12 (0)

N.I

N.I

0 (0)

N.S

Total-chol (mg/ml) mean (S.D.)a

167.8 (39)

162.4 (42)

145.1 (39)

145.3 (41)

 < 0.001

LDL-chol (mg/dl) mean (S.D.)a

94.1 (32)

88.1 (35)

78.8 (31)

79.6 (35)

 < 0.001

HDL-chol (mg/dl) mean (S.D.)a

52.8 (16)

51.8 (15)

46.8 (15)

47.3 (13)

 < 0.001

Triglycerides (mg/dl) mean (S.D.)a

98.7 (62)

103.9 (69)

89.9 (64)

82.1 (52)

 < 0.001

Non-HDL-chol (mg/dl) mean (S.D.)a

115.0 (35)

110.6 (39)

98.3 (35)

98 (39)

 < 0.001

ACEi/ARB n (%)

17,097 (62)

1793 (64)

4570 (70)

472 (73)

 < 0.001

Beta blockers n (%)

8923 (32)

1223 (43)

3482 (53)

435 (67)

 < 0.001

CCB n (%)

6690 (24)

677 (24)

1716 (26)

138 (21)

 < 0.01

Treat. Diabetes n (%)

7373 (27)

728 (26)

1665 (25)

134 (21)

 < 0.01

Fibrates n (%)

185 (0.7)

31 (1.1)

50 (0.8)

5 (0.8)

N.S

Simvastatin n (%)

10,350 (37.2)

44 (1.6)

0 (0.0)

0 (0.0)

 

Lovastatin n (%)

840 (3.0)

30 (1.1)

0 (0.0)

0 (0.0)

 

Pravastatin n (%)

1297 (4.7)

44 (1.6)

0 (0.0)

0 (0.0)

 

Fluvastatin n (%)

256 (0.9)

5 (0.2)

0 (0.0)

0 (0.0)

 

Atorvastatin n (%)

12,003 (43.2)

205 (7.3)

5864 (89.0)

516 (80.0)

 

Rosuvastatin n (%)

3049 (11.0)

116 (4.1)

712 (11.0)

113 (17.5)

 

Simvastatin + Ezetimibe n (%)

0 (0.0)

2363 (83.9)

0 (0.0)

0 (0.0)

 

Rosuvastatin + Ezetimibe n (%)

0 (0.0)

8 (0.3)

N.I

16 (2.5)

 
  1. Data reported as mean (S.D.) or as n (%). Opinion 05/2014 on “Anonymisation Techniques” drafted by the “European Commission Article 29 Working Party”, the analyses involving less than three patients were not reported, as potentially reconductable to single individuals. Therefore, results referred to ≤ 3 patients were reported as NI (not issuable)
  2. HIS high-intensity statins, NHIS non-HIS, Eze ezetimibe
  3. *ANOVA P value for differences between groups (i.e., if < 0.05 not all group are equivalent)
  4. aAnalyses performed on patients with at least one detection before index
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840